We have developed two functionalized β-sheet peptides (FBPs) and demonstrated that they can stabilize a variety of integral membrane proteins (IMPs), and most importantly allow covalent crosslinking of the IMPs onto solid supports via the highly selective click chemistry. The FBPs are promising tools for the preparation of IMP-based biomaterials or biosensors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c7cc08652k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
St-N, a novel alkaline derivative of stevioside, reverses docetaxel resistance by targeting lysosomes in vitro and in vivo.
PLoS One
December 2024
Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Drug resistance of cancers remains a major obstacle due to limited therapeutics. Lysosome targeting is an effective method for overcoming drug resistance in cancer cells. St-N (ent-13-hydroxy-15-kaurene-19-acid N-methylpiperazine ethyl ester) is a novel alkaline stevioside derivative with an amine group.
View Article and Find Full Text PDFRole of Toll-like receptor 2 during infection of Leptospira spp: A systematic review.
PLoS One
December 2024
International Vaccine Institute, Seoul, Republic of Korea.
The involvement of Toll-like receptor 2 (TLR2) in leptospirosis is poorly understood. Our systematic review examined its role across in-vitro, in-vivo, ex-vivo, and human studies. Original articles published in English up to January 2024, exploring the role of TLR2 during leptospirosis, were selected from databases including PubMed, Web of Science, Scopus, Trip, and Google Scholar.
View Article and Find Full Text PDFMirvetuximab Soravtansine in solid tumors: A systematic review and meta-analysis.
PLoS One
December 2024
Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Background: Mirvetuximab Soravtansine (MIRV) is a promising antibody‒drug conjugate (ADC) that targets folate receptor alpha (FRα), which is overexpressed in several types of solid tumors. In November 2022, MIRV was approved in the USA for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received 1-3 prior systemic treatment regimens. Therefore, high-quality evidence for its efficacy and safety in different cancers is urgently needed.
View Article and Find Full Text PDFTherapeutic dose prediction of α5-GABA receptor modulation from simulated EEG of depression severity.
PLoS Comput Biol
December 2024
Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, Canada.
Treatment for major depressive disorder (depression) often has partial efficacy and a large portion of patients are treatment resistant. Recent studies implicate reduced somatostatin (SST) interneuron inhibition in depression, and new pharmacology boosting this inhibition via positive allosteric modulators of α5-GABAA receptors (α5-PAM) offers a promising effective treatment. However, testing the effect of α5-PAM on human brain activity is limited, meriting the use of detailed simulations.
View Article and Find Full Text PDF[Efficacy and safety of topical antibiotic therapy in patients with acute external bacterial otitis: results of a retrospective study].
Vestn Otorinolaringol
December 2024
Sverzhevsky Research Clinical Institute of Otorhinolaryngology, Moscow, Russia.
Otitis externa is one of the most common diseases in otorhinolaryngological practice frequently requiring prescription of analgesic medications and antimicrobials. The total of 2714 patients were included in the retrospective study to evaluate bacterial etiology, effectiveness, and safety of topical empirical treatment of patients with diagnosed otitis externa during 2018-2023. The most common pathogens isolated were (38.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!